Ocugen Inc. has announced a definitive merger agreement with Carisma Therapeutics Inc. to create a new company focused on regenerative cell therapies for orthopedic diseases. The proposed reverse merger involves OrthoCellix, a wholly-owned subsidiary of Ocugen, and aims to form a Nasdaq-listed, late clinical-stage regenerative cell therapy company centered on orthopedic diseases. The combined company will prioritize the development of OrthoCellix's NeoCart® technology, an autologous cartilage implant designed to repair knee articular cartilage defects. Plans are underway to initiate a Phase 3 clinical trial for NeoCart®, endorsed by the U.S. Food and Drug Administration (FDA).
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocugen Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9482624-en) on June 23, 2025, and is solely responsible for the information contained therein.